Bao Pharmaceuticals Co. Ltd., a developer of subcutaneous biologic drugs, priced its IPO at HK$26.38 on Dec. 2, aiming to raise about HK$1 billion (US$128 million). Bao expects net proceeds of HK$921.5 million after expenses, which will fund its “two-anti” strategy – developing both antibody and antibiotic drugs worldwide, mainly in China, the U.S. and Europe.

Biopharmas raising money in public or private financings, including: Adial, Scilex.

Protego Biopharma Inc. closed an oversubscribed $130 million series B financing that will be used to advance PROT-001, the company’s treatment for amyloid light (AL) chain amyloidosis. a plasma cell disorder where the cells produce abnormal, misfolded immunoglobulin light chain proteins.

Biopharmas raising money in public or private financings, including: Faron, Nuvalent, Pharmacyte, Tempest, Zetagen.

Biopharmas raising money in public or private financings, including: Azitra, Enlivex, Fibrobiologics, Mindimmune, Scilex, Vaxil, Verrica.

Biopharmas raising money in public or private financings, including: Bioatla, Inhibikase.

Biopharmas raising money in public or private financings, including: Biovaxys, Cassidy, Moderna.

Biopharmas raising money in public or private financings, including: AI Proteins, Fibrobiologics, Genmab, HCW, Hemostemix, Lifordi, Mendus, Nervgen, Nuvalent, Olema, Seragene, Skeletalis.